长春高新(000661.SZ)子公司褪黑素颗粒上市申请获受理

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. ("Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the domestic production drug registration application of melatonin granules, indicating progress in its product development in the pediatric neuropsychiatric field [1]. Group 1 - The melatonin granules are developed by Jinsai Pharmaceutical and are classified as a Category 4 chemical drug [1]. - The product aims to improve sleep difficulties associated with neurodevelopmental disorders in children by activating the MT1 and MT2 receptors in the suprachiasmatic nucleus [1]. - The indication for the product is specifically targeted at children experiencing sleep onset issues due to neurodevelopmental disorders [1].